



Intercell AG announces Q3 2008 results and updates on development programs:

**Approvals for Japanese Encephalitis vaccine in U.S., Europe and Australia on track for 2008
– All development programs progressing according to plan – Profitability expected for full
year 2008 – Strong financial and strategic position**

Intercell successfully advanced parallel regulatory processes in all key markets for travelers and military personnel – Vaccine against Japanese Encephalitis expected to obtain market approval in the U.S., Europe and Australia in 2008 – U.S. Defense Logistics Agency Request for Proposal (RFP) for purchase of Japanese Encephalitis (JE) vaccine for U.S. military in negotiation

- » **United States:** On October 20, the U.S. Food and Drug Administration (FDA) gave positive feedback on Intercell's application to market its vaccine against Japanese Encephalitis; Intercell and the agency are working towards the earliest possible approval – ACIP meeting discussion on future recommendation of JE vaccine held on October 22/23 with formal decision expected at the February 2009 meeting
- » **Europe:** Approval process advancing according to plan – Intercell expects a positive opinion from EMEA in December 2008
- » **Australia:** Positive approval decision is expected in December 2008
- » Intercell has geared up manufacturing efforts to ensure timely product delivery to the U.S. military by the end of 2008 and for commercial product launch in the United States, Europe and Australia in early 2009

Integration of recent acquisition of IOMAI successfully implemented – Focus now on aggressively progressing Travelers' Diarrhea patch vaccine and leveraging patch-based products and technologies

- » Strategic focus on late-stage development and industrialization of the Travelers' Diarrhea patch vaccine and Pandemic Influenza patch vaccine. In addition, investigation of the use of the patch technology in new vaccine applications has been effectively initiated
- » Start of pivotal Phase III for Travelers' Diarrhea patch vaccine expected in H1 2009
- » Start of Phase II Pandemic flu vaccine expected in H1 2009



Nosocomial infections – S. aureus vaccine and Pseudomonas vaccine progressing in clinical programs – All other development programs and partnerships on track

- » Pseudomonas: Start of clinical Phase II/III trials in ventilated Intensive Care Unit patients expected in December 2008
- » S. aureus: Phase II study by Intercell's partner Merck & Co. Inc. in cardiothoracic surgery progressing well with efficacy data expected by mid 2009 – further Phase II study initiated in hemodialysis patients with late-stage kidney disease, expanding the field of application of the vaccine
- » Pneumococcus: After full preparation of clinical strategy, start of clinical Phase I trials planned for early 2009

Results from 6-month follow-up of Intercell's therapeutic Hepatitis C vaccine showed statistically significant and long-term antiviral effect in Phase II patients

- » Intercell is currently examining options for future development including the formulation of the vaccine with IC31® and combination with other antiviral therapies

Therapeutic Monoclonal Antibodies

- » Strategic partnering process initiated to extract maximum value out of this franchise and to keep internal focus on vaccines

Financial Statements

- » Intercell's aggregate revenues doubled from EUR 12.6 m in the 9 months ended September 30, 2007 to EUR 25.3 m in the same period of 2008
- » Intercell's net loss decreased by EUR 8.3 m, or 37.6 percent, to EUR 13.8 m in the first 9 months of 2008 from EUR 22.1 m in the same period of 2007
- » As of September 30, 2008 Intercell had liquid funds of EUR 209.0 m, of which EUR 49.1 m was cash and EUR 159.9 m was available-for-sale financial assets. Cash preservation is the principal goal of Intercell's short-term cash management strategy. The impact of the current conditions in the capital markets on the cash portfolio is therefore minimal.

Key Figures – Financial Highlights

EUR in thousands	3 months ended		9 months ended		Year ended
	Sept 30, 2008	Sept 30, 2007	Sept 30, 2008	Sept 30, 2007	Dec 31, 2007
Revenues	7,641	7,375	25,283	12,559	53,349
Net profit/(loss)	(5,140)	(6,514)	(13,789)	(22,085)	5,009
Net operating cash flow	24,956	(12,978)	(430)	(27,480)	41,686
Cash and marketable securities, end of period	208,952	218,580	208,952	218,580	287,571

About Intercell AG

Intercell AG is a growing biotechnology company which focuses on the design and development of novel vaccines for the prevention and treatment of infectious diseases with substantial unmet medical need. The Company develops antigens and adjuvants which are derived from its proprietary technology platforms and has in-house GMP manufacturing capabilities. Based on these technologies, Intercell has strategic partnerships with a number of global pharmaceutical companies, including Novartis, Merck & Co., Inc., Wyeth, Sanofi Pasteur, Kyowa Hakko Kirin, and the Statens Serum Institut.

The Company's leading product, a prophylactic vaccine against Japanese Encephalitis, successfully concluded pivotal Phase III clinical trials in 2006 and is currently in the process of marketing approval in the US, Europe, Australia and Canada. Marketing approval in the US, Europe and Australia is expected for the second half of 2008.

The company's broad development pipeline includes a Travelers' Diarrhea vaccine (patch) in Phase II (start of Phase III expected in 2009), a Pseudomonas vaccine in Phase II, as well as an pandemic Influenza Vaccine Enhancement patch, a partnered S. aureus vaccine in Phase II and four products focused on infectious diseases in preclinical development.

Intercell is listed on the Vienna stock exchange under the symbol "ICLL".

For more information please visit: www.intercell.com

Contact Intercell AG

Lucia Malfent

Head of Corporate Communications

Campus Vienna Biocenter 3, A-1030 Vienna

P: +43-1-20620-1303

Mail to: LMalfent@intercell.com

This communication expressly or implicitly contains certain forward-looking statements concerning Intercell AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Intercell AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Intercell AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.